Royal Oak, Mich.-based liquid biopsy startup Oncocell MDx Inc. reeled in $22.2 million in a series B financing led by Savitr Capital, with participation from existing investors. The company, which has raised a total of $30 million to date, plans to use the proceeds to support ongoing development of its pan-disease immunogenomics platform and commercialization of its novel noninvasive blood-based tests.
BEIJING – Biologics developer Hisun Bioray Bio-pharmaceutical Co. Ltd., a subsidiary of Chinese state-owned drugmaker Zhejiang Hisun Pharmaceutical Co. Ltd., received ¥3.8 billion (US$540 million) from Hong Kong investor PAG for a 58% stake in the company.
DUBLIN – Inotrem SA raised €39 million (US$42.9 million) in a series B round to finance a phase IIb trial of its first-in-class septic shock drug candidate, nangibotide, along with a candidate biomarker that may enable it to select patients most likely to benefit from the therapy.
TAIPEI, Taiwan – Budding Taiwanese startup Elixiron Immunotherapeutics Inc. closed a $10.5 million series A1 financing to further expand its technology platform and drive its drug candidates toward clinical development.
Foamix Pharmaceuticals Ltd., an Israeli specialty pharma developing foam-based formulations of minocycline for moderate-to-severe acne and rosacea, has secured up to $64 million in financing from Perceptive Advisors and Orbimed, its two largest shareholders. The funds, comprised of loans and proceeds of a registered direct offering, are expected to support potential commercial launches for FMX-101 and FMX-103, pending FDA approval, the company said.
Kronos Bio Inc. closed a $105 million series A preferred stock financing, shored up by a board composed of longtime pharma executives that includes the company CEO and president, Norbert Bischofberger, the former Gilead Sciences Inc. R&D executive vice president and chief science officer.
Gns Healthcare landed $23 million in a series D fundraising round led by Cigna Ventures. Cigna's wholly owned corporate venture fund joined Amgen Ventures, Celgene Corp., Echo Health Ventures, Alexandria Venture Investments and Gary Loveman, former Caesar's CEO and Aetna division president, in the latest round.
Trefoil Therapeutics Inc.'s $28 million from an oversubscribed series A financing will let the company finish a phase IIa proof-of-concept study as researchers edge toward attacking corneal endothelial dystrophy, including Fuchs dystrophy, a disease that leads to the deterioration of the endothelial layer on the back surface of the cornea.
LONDON – AM-Pharma BV has raised €116 million (US$130.7 million) in a series E round to fund phase III development of its recombinant alkaline phosphatase, Recap, in the treatment of sepsis-associated acute kidney injury (SA-AKI).